Skip to main content

Specialty Pharmacy

  • Pfizer decides against splitting Essential Health, Innovative Health divisions

    NEW YORK — After a period of evaluation, Pfizer announced Monday that its board of directors and executive leadership team had decided not to split the company into two separate companies, Pfizer Innovative Health and Pfizer Essential Health. The two will remain separately managed units within Pfizer. 
     

  • FDA approves Janssen’s Stelara to treat Crohn’s disease

    SILVER SPRING, Md. — Janssen Biotech announced Monday that the Food and Drug Administration had approved its Stelara (ustekinumab) to treat moderately to severely active Crohn’s disease.  
     
    It is now indicated for adults with Crohn’s disease who have failed or were intolerant to corticosteroid or immunomodulator treatments, but never failed treatment with a tumor necrosis factor (TNF) blocker, or who failed or were intolerant of one or more TNF blocker treatment. 
     

  • PhRMA brings scientists to Capitol Hill

    WASHINGTON — The Pharmaceutical Research and Manufacturers of America (PhRMA) on Wednesday brought 60 of its member companies’ researchers to Capitol Hill for meetings with members of Congress. The researchers will discuss with lawmakers how they can support developing new, innovative medicines. 
     

  • Allergan acquires Akarna Therapeutics

    DUBLIN — On the same day that it announced the acquisition of Tobira Therapeutics, Allergan acquired Akarna Therapeutics, a biotech company that, like Tobira, focuses on developing treatments for nonalcoholic steatohepatitis (NASH), a severe type of fatty liver disease.
     

  • Report: Sanofi files suit over Merck’s Lantus biosimilar

  • Allergan to acquire Tobira Therapeutics

    DUBLIN and SAN FRANCISCO — Allergan has announced an acquisition aimed at making it a leader in the development of treatment for nonalcoholic steatohepatitis (NASH), a disease state seeing increased interest from drug makers. The company will be acquiring clinical-stage biotech company Tobira Therapeutics in a deal with a total potential value of $1.69 billion.
     

  • Industry responds to Biosimilar User Fee Act letter

    SILVER SPRING, Md. — The Food and Drug Administration on Friday released the Biosimilar User Fee Act (II) performance goals letter, drawing support from trade groups representing biotechnology companies. 
     

  • CPPA accredits KloudScript’s specialty-at-retail model

    OAKBROOK TERRACE, Ill. — The Center for Pharmacy Practice Accreditation (CPPA) has accredited specialty pharmacy care network KloudScript’s partnership with Illinois independent pharmacy Doc’s Pharmacy, the company announced Tuesday. This marks the first time a specialty-at-retail provider and a pharmacy have been given a joint accreditation from CPPA. 
     
X
This ad will auto-close in 10 seconds